



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294TN1995PLCO30698

Date: March 31, 2025

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001.	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
Scrip Code: 532989	Scrip Code: BAFNAPH

Dear Sir/Madam,

Subject: Disclosure under Regulation 7(2) SEBI (Prohibition of Insider Trading) Regulations, 2015

We hereby enclose the Disclosure under Regulation 7(2)(a) of SEBI (Prohibition of Insider Trading) Regulations, 2015, received from M/s. SRJR Lifesciences LLP, a Promoter of Bafna Pharmaceuticals Limited ("The Company"), regarding the sale of 31,45,296 Equity Shares of the Company on March 27, 2025 ("T Day") and March 28, 2025 ("T+1 Day") pursuant to Offer for Sale by M/s. SRJR Lifesciences LLP through Stock Exchange Mechanism made in accordance with SEBI circular no. SEBI/HO/MRD/MRD-PoD-3/P/CIR/2023/10 dated January 10, 2023.

This submission is made pursuant to Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

We kindly request you to take the disclosure on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

Mohanachandran A

Company Secretary & Compliance Officer

SRJR LIFESCIENCES LLP

LLPIN: AAR-4517

ILABS CENTRE BUILDING NO.3, NO.18, SOFTWARE UNITS LAYOUT, MADHAPUR,
HYDERABAD, TELANGANA – 500 081

Date: March 29, 2025

To

Bafna Pharmaceuticals Limited

Bafna Towers, 299
Thambu Chetty Street
Chennai – 600 001
Tamil Nadu

Dear Sir/ Madam,

Sub: Filing of report under Regulation 7(2)(a) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended (“SEBI Insider Trading Regulations”).


This is with reference to the notice dated March 26, 2025 (“Notice”) filed by us with the Stock Exchanges, pursuant to which SRJR Lifesciences LLP, being the Promoter of Bafna Pharmaceuticals Limited (“Company”) proposed to sell up to 31,45,296 Equity Shares of the Company, (representing 13.30% of the total paid up equity share capital of the Company) (“Offer Shares”), on March 27, 2025, (“T day”) (for non-Retail Investors only) and on March 28, 2025 (“T+1 day”) (for Retail Investors and for non-Retail Investors who choose to carry forward their un-allotted bids) through a separate, designated window of the BSE Limited (the “BSE”) and the National Stock Exchange of India Limited (“NSE”), the “Stock Exchanges”, by way of an offer for sale through “Comprehensive Framework on Offer for Sale of Shares through Stock Exchange Mechanism” issued by the Securities and Exchange Board of India (“SEBI”) through its circular no. SEBI/HO/MRD/MRD-PoD-3/P/CIR/2023/10 dated January 10, 2023 (the “OFS Circular”), and paragraph 19.1.5.2 of chapter 1 of the “Master Circular for Stock Exchange and Clearing Corporation- Trading” issued by SEBI through its circular no. SEBI/HO/MRD-PoD2/CIR/P/2024/00181 dated December 30, 2024 read with (a) “Revised Operational Guidelines for Offer for Sale (OFS) Segment” issued by BSE by way of its notice bearing no. 20240701-19 dated July 1, 2024 and, to the extent applicable, the previous circulars issued by BSE in this regard; (b) “Revised operating guidelines of Offer for Sale” issued by NSE by way of its circular bearing no. NSE/CMTR/62927, dated July 12, 2024 to the extent applicable, the previous notices issued by NSE in this regard (together with the OFS Circular, the “SEBI OFS Guidelines”), and such offer for sale is referred to as the “Offer”.

In this regard, we wish to inform you that we have sold 28,30,766 Equity Shares to non-retail investors on the basis of the valid bids received from non-retail investors on T Day i.e., March 27, 2025 and sold 3,14,530 Equity Shares to retail investors on T+1 day i.e., on March 28, 2025, in aggregate, amounting to 13.30% of the equity share capital of the Company.

In compliance with Regulation 7(2)(a) of the SEBI Insider Trading Regulations, we are hereby notifying the Company of the information regarding disposal of the Equity Shares within 2 trading days of such transactions.

Enclosed is the report in the format prescribed in Form C of the circular bearing number SEBI/HO/ISD/ISD/CIR/P/2021/19 dated February 9, 2021, issued by the Securities and Exchange Board of India.

RS




Tel No: 040-40484444 Email: cs@srjrlifesciencesllp.com


The above is for your information and records.

Yours sincerely,

On behalf of SRJR Lifesciences LLP



Seshadri Rangarajan
Authorised Signatory



FORM C


**Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7(2) read with Regulation 6(2) - Continual Disclosure]**

Name of the company: Bafna Pharmaceuticals Limited


ISIN of the company: INE878101022

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

1 Name, PAN, CIN/DIN, & address with contact nos.	2 Category of Person (Promoter/ Member of the promoter group/ designated person/ Directors/ Immediate relatives/ others etc.)	3 Securities held prior to disposal		5 Securities Disposed			6 No.		7 Value	8 Transaction type (Purchase/ Sale/ Pledge/ Revocation/ Invocation / Others – please specify)	9 Securities held post acquisition/disposal		10 No. and % of shareholdin g	11 Date of allotment advice/ acquisition of shares/ disposal of shares, specify From To	12 Date of intimation to company	13 Mode of acquisition/ disposal (on market/public rights/ preferential offer / off market/ Inter-se transfer, ESOPs etc.)	14 Exchange on which the trade was executed	15
		Type of Security (For eg. – Shares, Warrants, Convertible Debentures, Rights entitlement etc.)	No. and % of shareholdin g	Type of Securities (For eg. – Shares, Warrants, Convertible Debentures, Rights entitlement etc.)	Type of securities (For eg. – Shares, Warrants, Convertible Debentures, Rights entitlement etc.)													



Name: SRJR Lifescience s LLP ("Promoter ") PAN: AECFS120 8Q Address: iLabs Centre, Building No. 3, No. 18, Software Units Layout, Madhapur, Hyderabad, Telangana - 500081 Contact No. +91 70326 39418	Promoter	Equity Shares	2,07,85,312 Equity Shares and 87.86% of the paid-up equity share capital of the Company	Equity Shares	28,30,766 Equity Shares (11.97% of the paid-up Equity Shares) ⁽¹⁾	₹ 20,38,15,152 (2)	Offer for Sale of Equity Shares by the Promoter through the stock exchange mechanism	Equity Shares	1,79,54,546 Equity Shares and 75.90% of the paid-up equity share capital of the Company	March 27, 2025	March 29, 2025	On market through an Offer For Sale of Equity Shares by the Promoter through the stock exchange mechanism	BSE & NSE (Trade was executed on both the exchange s)
Name: SRJR Lifescience s LLP ("Promoter ") PAN: AECFS120 8Q Address: iLabs Centre, Building No. 3, No. 18, Software Units Layout, Madhapur, Hyderabad, Telangana - 500081 Contact No. +91 70326 39418	Promoter	Equity Shares	1,79,54,546 Equity Shares and 75.90% of the paid-up equity share capital of the Company	Equity Shares	3,14,530 Equity Shares (1.33% of the paid-up Equity Shares) ⁽³⁾	₹ 2,26,46,160 (4)	Offer for Sale of Equity Shares by the Promoter through the stock exchange mechanism	Equity Shares	1,76,40,016 Equity Shares and 74.57% of the paid-up equity share capital of the Company	March 28, 2025	March 29, 2025	On market, through Offer For Sale of Equity Shares by the Promoter through the stock exchange mechanism	BSE & NSE (Trade was executed on both the exchange s)



(Handwritten signature)

